UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy

The oncologist (Dayton, Ohio), 2002-08, Vol.7 (S4), p.2-8

Baselga, José

2002

Volltextzugriff (PDF)

Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study

Journal of thoracic oncology, 2006-10, Vol.1 (8), p.847-855

2006

Volltextzugriff (PDF)

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs

European Journal of Cancer, 2003-07, Vol.39 (10), p.1348-1354

2003

Volltextzugriff (PDF)

EGFR blockade with ZD1839 (“Iressa”) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma

International journal of radiation oncology, biology, physics, 2003-03, Vol.55 (3), p.713-723

2003

Volltextzugriff (PDF)

Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor

Pharmaceuticals (Basel, Switzerland), 2024-02, Vol.17 (2), p.208

2024

Volltextzugriff (PDF)

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Clinical cancer research, 2005-05, Vol.11 (10), p.3750-3757

2005

Volltextzugriff (PDF)

Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck

Clinical cancer research, 2005-04, Vol.11 (8), p.2879-2882

2005

Volltextzugriff (PDF)

EGFR modulates complement activation in head and neck squamous cell carcinoma

BMC cancer, 2020-02, Vol.20 (1), p.121-121, Article 121

2020

Volltextzugriff (PDF)

Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity

Anti-cancer agents in medicinal chemistry, 2018-01, Vol.18 (5), p.747-756

2018

Volltextzugriff (PDF)

FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets

The oncologist (Dayton, Ohio), 2003-08, Vol.8 (4), p.303-306

2003

Volltextzugriff (PDF)

Pharmacokinetic properties and bioequivalence of gefitinib 250 mg in healthy Korean male subjects

Translational and clinical pharmacology, 2021-09, Vol.29 (3), p.171-179

2021

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?

The oncologist (Dayton, Ohio), 2002-08, Vol.7 (S4), p.31-39

Arteaga, Carlos L.

2002

Volltextzugriff (PDF)

AKT inactivation causes persistent drug tolerance to EGFR inhibitors

Pharmacological research, 2015-12, Vol.102, p.132-137

2015

Volltextzugriff (PDF)

Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer

Journal of Cancer, 2015-01, Vol.6 (6), p.568-574

2015

Volltextzugriff (PDF)

Cytotoxicity of ZnO Paper against Cancer Cells

Sensors and materials, 2021-01, Vol.33 (10), p.3389

2021

Volltextzugriff (PDF)

Optimization of gefitinib analogues with potent anticancer activity

Bioorganic & medicinal chemistry letters, 2014-11, Vol.24 (22), p.5247-5250

2014

Volltextzugriff (PDF)

Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation

Molecular cancer therapeutics, 2004-04, Vol.3 (4), p.465-472

2004

Volltextzugriff (PDF)

Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cells

International journal of cancer, 2004-01, Vol.108 (3), p.464-472

2004

Volltextzugriff (PDF)

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

Annals of oncology, 2003-06, Vol.14 (6), p.922-930

2003

Volltextzugriff (PDF)

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

Gynecologic oncology, 2008-01, Vol.108 (1), p.42-46

2008

Volltextzugriff (PDF)

An efficient construction of quinazolin-4(3H)-ones under microwave irradiation

ARKIVOC, 2007-02, Vol.2007 (1), p.40-50

2007

Volltextzugriff (PDF)

Interstitial lung disease associated with drug therapy

British journal of cancer, 2004-08, Vol.91 (S2), p.S18-S23

2004

Volltextzugriff (PDF)

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer

British journal of cancer, 2004-07, Vol.91 (2), p.208-212

2004

Volltextzugriff (PDF)

The effects of gefitinib in tamoxifen‐resistant and hormone‐insensitive breast cancer: A phase II study

International journal of cancer, 2010-04, Vol.126 (8), p.1806-1816

2010

Volltextzugriff (PDF)

Light of DNA-alkylating agents in castration-resistant prostate cancer cells: a novel mixed EGFR/DNA targeting combi-molecule

American journal of translational research, 2017-01, Vol.9 (7), p.3245-3257

2017

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(166)
Mit Volltextzugriff
(174)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(140)
Life Sciences & Biomedicine
(134)
Iressa
(131)
Gefitinib
(129)
Humans
(127)
Oncology
(97)
Biological And Medical Sciences
(61)
Medical Sciences
(59)
Female
(54)
Quinazolines - Therapeutic Use
(54)
Antineoplastic Agents - Therapeutic Use
(49)
Zd1839
(49)
Male
(47)
Lung Neoplasms - Drug Therapy
(46)
Middle Aged
(43)
Quinazolines - Pharmacology
(43)
Aged
(41)
Receptor, Epidermal Growth Factor - Antagonists & Inhibitors
(41)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(40)
Epidermal Growth Factor Receptor
(39)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

British Journal Of Cancer
(14)
The Oncologist
(7)
The oncologist
(7)
Lung Cancer
(6)
Annals Of Oncology
(5)
Clinical Cancer Research
(5)
Anticancer Research
(4)
European Journal Of Cancer Supplements
(4)
International Journal Of Cancer
(4)
肺癌
(4)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy

Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study

Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs

EGFR blockade with ZD1839 (“Iressa”) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma

Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck

EGFR modulates complement activation in head and neck squamous cell carcinoma

Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity

FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets

Pharmacokinetic properties and bioequivalence of gefitinib 250 mg in healthy Korean male subjects

Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?

AKT inactivation causes persistent drug tolerance to EGFR inhibitors

Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer

Cytotoxicity of ZnO Paper against Cancer Cells

Optimization of gefitinib analogues with potent anticancer activity

Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation

Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cells

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

An efficient construction of quinazolin-4(3H)-ones under microwave irradiation

Interstitial lung disease associated with drug therapy

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer

The effects of gefitinib in tamoxifen‐resistant and hormone‐insensitive breast cancer: A phase II study

Light of DNA-alkylating agents in castration-resistant prostate cancer cells: a novel mixed EGFR/DNA targeting combi-molecule

Suchergebnisse filtern